TrialJAMA network open2024

Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer: A Secondary Analysis of the SOLD Randomized Clinical Trial.

Heikki Joensuu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.